CureVac (NASDAQ:CVAC) Trading Down 5.8% - Time to Sell?

Shares of CureVac (NASDAQ:CVAC - Get Free Report) fell 5.8% on Monday . The stock traded as low as $3.52 and last traded at $3.57. 409,255 shares were traded during mid-day trading, a decline of 65% from the average session volume of 1,157,037 shares. The stock had previously closed at $3.79.

CureVac Stock Performance

The firm has a market cap of $835.07 million, a P/E ratio of 6.78 and a beta of 2.51. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $3.52 and a 200-day simple moving average of $3.22.

Institutional Investors Weigh In On CureVac

Several institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of CureVac by 26.9% in the 3rd quarter. Signaturefd LLC now owns 27,970 shares of the company's stock worth $82,000 after purchasing an additional 5,927 shares in the last quarter. Private Advisor Group LLC purchased a new stake in shares of CureVac during the third quarter valued at $30,000. International Assets Investment Management LLC bought a new stake in CureVac in the 3rd quarter worth about $35,000. Ballentine Partners LLC raised its position in CureVac by 58.6% in the 3rd quarter. Ballentine Partners LLC now owns 22,755 shares of the company's stock worth $67,000 after buying an additional 8,406 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company's stock valued at $127,000 after acquiring an additional 16,792 shares during the period. Institutional investors own 17.26% of the company's stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.